Sanara expects OsStic bone void filler to be introduced to the market in Q1 2027
Overview
US surgical medtech firm's Q2 revenue rose 9% yr/yr to $28.1 mln
Company posted Q2 net loss from continuing operations, citing higher SG&A and interest expenses
Sanara to be acquired by MIMEDX in a deal pending customary closing conditions
Result drivers
Soft tissue product growth - Q2 revenue growth was driven by an 11% increase in sales of soft tissue repair products, including CellerateRX Surgical, BIASURGE and FORTIFY TRG
Higher SG&A and interest expenses - Increased selling, general and administrative costs, along with higher interest expense, contributed to the Q2 net loss from continuing operations
Legal and advisory costs - Legal and advisory expenses related to corporate strategic initiatives, including the pending MIMEDX acquisition, raised operating costs
Analyst coverage and valuation
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
SMTI•
